As a final consideration, based on the reliability of the FIS assay to predict the clinical response to drugs demonstrated here for CFTR clinical modulators, CRC-based nasal organoid models may represent a powerful tool with which to test the ability of innovative experimental drugs or therapeutic approaches to rescue CFTR function. This evidence concerns the gene CFTR and colorectal carcinoma.